GALMED PHARMACEUTICALS LTD. Principal Investment Gain (Loss)
GALMED PHARMACEUTICALS LTD. (GLMD) reported Principal Investment Gain (Loss) of $2.50 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PrincipalInvestmentGainsLosses · last filed 2026-03-31
| Period end | Principal Investment Gain (Loss) 12 month |
|---|---|
| 2025-12-31 | $2.50M 20-F · filed 2026-03-31 |